Present Situation and Prospect of Antiviral Treatments for COVID-19

doi:10.19803/j.1672-8629.2020.03.01

Abstract

Abstract: In December 2019, a series of pneumonia cases of unknown cause emerged in Wuhan, Hubei Province. In January 2020, a new type of coronavirus (2019-nCoV) was isolated. With the outbreak of COVID-19, the number of severe, critical and death cases is increasing gradually. In the diagnosis and treatment program of our country, the oral administration of lopinavir/ritonavir and the atomization of α-interferon were used, and ribavirin, chloroquine phosphate and abidol can also be used for antiviral treatment.The plasma of convalescent patients can be used for the treatment of severe and critical patients. Recently, a United States report that the first case of 2019-nCoV infection confirmed patient have been significantly improved after treatment with remdesivir. Fabiravir is also considered to have potential efficacy. Antiviral treatment is the key to the treatment of severe and critical diseases. In this paper, the present situation and prospect of selective antiviral treatments for COVID-19 is reviewed.

Key words: COVID-19, antiviral treatments

CLC Number:

R978.7

TIAN Di, WANG Lin, GE Ziruo, CUI Shuping, CHEN Zhihai. Present Situation and Prospect of Antiviral Treatments for COVID-19[J]. Chinese Journal of Pharmacovigilance, 2020, 17(3): 129-135.

References

[1] Zhu N, Zhang D, Wang W.et al.A Novel Coronavirus from Patients with Pneumonia in China, 2019[J]. N Engl J Med, 2020, 382(8):727-733.
[2] Holshue ML, DeBolt C, Lindquist S, et al. First Case of2019 Novel Coronavirus in the United States[J]. N Engl J Med, 2020 Jan 31. DOI: 10.1056/NEJMoa2001191.
[3] Mulangu S, Dodd LE, Davey RT Jr, et al.A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics[J]. N Engl J Med, 2019, 381(24):2293-2303. doi: 10.1056/NEJMoa1910993.
[4] Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease[J]. mBio, 2018, 9(2). pii: e00221-18. doi: 10.1128/mBio.00221-18.
[5] Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum Antiviral GS-5734 Inhibits Both Epidemic and Zoonotic Coronaviruses[J]. Sci Transl Med, 2017, 9(396). pii: eaal3653. doi: 10.1126/ scitranslmed.aal3653.
[6] de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection[J]. Proc Natl Acad Sci U S A, 2020 Feb 13. pii: 201922083. doi: 10.1073/pnas.1922083117.
[7] Brown AJ, Won JJ, Graham RL, et al.Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronav- iruseswith a highly divergent RNA dependent RNA polymerase[J]. Antiviral Res, 2019,169:104541. doi: 10.1016/j.antiviral.2019.104541.
[8] Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro[J]. Cell Research, 2020 Feb 4. doi: 10. 1038/s41422-020-0282-0.
[9] 赵旭,周辛波,钟武,等.抗病毒药物—法匹拉韦[J].临床药物治疗杂志,2015,13(4): 16-20.
[10] 王先堃,孙娜,陈志海.法匹拉韦抗病毒治疗研究进展[J].中国新药杂志, 2019,28(15): 1824-1827.
[11] Agostini ML, Pruijssers AJ, Chappell JD, et al.Small-Molecule Antiviral β-d-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance[J]. J Virol, 2019, 93(24):1-12.
[12] Warren TK, Wells J, Panchal RG, et al.Protection against filovirus diseases by a novel broad-spectrum nucleoside ana- logue BCX4430[J]. Nature, 2014, 508(7496):402-405.
[13] 国家卫生健康委员会办公厅,国家中医药管理局办公厅.《新型冠状病毒肺炎诊疗方案》(试行第七版)[EB/OL].(2020- 03-03)[2020-03-04]. http://www.gov.cn/zhengce/zhengceku/ 2020-03/04/content_5486705.htm.
[14] deWilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture[J]. Antimicrob Agents Chemother, 2014, 58(8):4875-4884.
[15] Chu CM, Cheng VC, Hung IF, et al.Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings[J]. Thorax, 2004, 59(3):252-256.
[16] Chan JF, Yao Y, Yeung M, et al.Treatment with lopinavir/riton- avir or interferon-β1b improves outcome of MERS-CoV infection in a non-human primate model of common marmoset[J]. J Infect Dis, 2015, 212(12):1904-1913.
[17] Arabi YM, Asiri AY, Assiri AM, et al.Treatment of Middle East Respiratory Syndrome With a Combination of Lopinavir/Ritonavir and interferon-β1b (MIRACLE Trial): Statistical Analysis Plan for a Recursive Two-Stage Group Sequential Randomized Controlled Trial[J]. Trials, 2020, 21(1):8.
[18] Sheahan TP, Sims AC, Leist SR, et al.Comparative therapeutic efficacy of remdesivir and combination lopinavir, and interferon beta against MERS-CoV[J]. Nat Commun, 2020 , 11(1):222.
[19] Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019- nCoV) in vitro[J]. Cell Res, 2020 Feb 4. doi: 10.1038/s41422- 020-0282-0.
[20] Morra ME, Van Thanh L, Kamel MG, et al.Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta-analysis[J]. Rev Med Virol, 2018, 28(3):e1977.
[21] Leong HN, Ang B, Eamest A.Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003[J]. Trop Med Int Health, 2004 , 9(8):923-927.
[22] Stroher U, DiCaro A, Li Y, et al. Severe acute respiratory syndrome- related coronavirus is inhibited by Interferon-alpha[J]. J Infect Dis, 2004, 189(7):1164-1167.
[23] Stockman LJ, Bellamy R, Garner P.SARS: Systematic Review of Treatment Effects[J]. PLoS Med, 2006, 3(9):e343.
[24] Ferron F, Subissi L, Silveira De Morais AT, et al. Structural and Molecular Basis of Mismatch Correction and Ribavirin Excision From Coronavirus RNA[J]. Proc Natl Acad Sci U S A, 2018, 115(2):E162-E171.
[25] Akira S, Uematsu S, Takeuchi O.Pathogen Recognition and Innate Immunity[J]. Cell, 2006, 124(4):783-801.
[26] Chen F, Chan KH, Jiang Y, et al.In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral com- pounds[J].J Clin Virol, 2004, 31(1):69-75.
[27] Haagmans BL, Kuiken T, Martina BE, et al.Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques[J].Nat Med, 2004, 10(3):290-293.
[28] Omrani AS, Saad MM, Baig K, et al.Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection:a retrospective cohort study[J]. Lancet Infect Dis, 2014,14:1090-1095.
[29] Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and interferon therapy for critically ill patients with Middle East Respiratory Syndrome: A multicenter observational study[J]. Clin Infect Dis, 2019 Jun 25. pii: ciz544. doi: 10.1093/cid/ciz544.
[30] 郑阳,王全意.利巴韦林和干扰素-ɑ联合应用治疗中东呼吸综合征冠状病毒感染的生物信息学分析[J].中华流行病学杂志, 2016, 37(2) :291-293.
[31] Khamitov RA, Loginova Sla, Shchukina VN, et al.Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures[J]. Vopr Virusol, 2008, 53(4):9-13.
[32] 陈军,凌云,席秀红,等.洛匹那韦利托那韦和阿比多尔用于治疗新型冠状病毒肺炎的有效性研究[J].中华传染病杂志, 2020, 38( 00 ): E008-E008. DOI: 10.3760/cma.j.cn311365- 20200210-00050.
[33] Wang L, Shi W, Chappell JD, et al. Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on MERS-CoV Spike to avoid neutralization escape[J]. J Virol, 2018, 92(10). pii: e02002-17. doi: 10.1128/JVI.02002-17.
[34] Niu P, Zhang S, Zhou P, et al.Ultrapotent human neutralizing antibody repertoires against Middle East respiratory syndrome coronavirus from a recovered patient[J]. J Infect Dis, 2018, 218(8):1249-1260. doi: 10.1093/infdis/jiy311.
[35] Chen Z, Bao L, Chen C, et al.Human neutralizing monoclonal antibody inhibition of Middle East respiratory syndrome coronavirus replication in the common marmoset[J]. J Infect Dis, 2017, 215(12):1807-1815.
[36] Zhang S, Zhou P, Wang P, et al.Structural definition of a unique neutralization epitope on the receptor-binding domain of MERS-CoV spike glycoprotein[J]. Cell Rep, 2018, 24(2):441-452.
[37] Coughlin MM, Babcook J, Prabhakar BS, et al.Human mono- clonal antibodies to SARS-coronavirus inhibit infection by different mechanisms[J]. Virology, 2009, 394(1):39-46.
[38] 卢帅,秦堃,谭文杰.中东呼吸综合征冠状病毒的实验室检测以及疫苗和治疗研究进展[J].中华实验和临床病毒学杂志, 2016, 30(6):582-586.
[39] Tian X, Li C, Huang A, et al.Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody[J]. Emerg Microbes Infect, 2020, 9(1): 382-385.
[40] Nie Y, Wang G, Shi X, et al.Neutralizing Antibodies in Patients with Severe Acute Respiratory Syndrome-Associated Coronavirus Infection[J]. J Infect Dis, 2004, 190(6):1119-26.